A Phase II, Multi-centre, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of
malignant brain tumour in adults and can be resistant to conventional therapies. The purpose
of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumour
responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when
delivered directly into the tumour followed by the administration of intravenous
pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or
until disease progression.
Funding Source-FDA OOPD
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society